This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Dalhousie University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Vaccine · 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Vaccine · 2012
Latest funding
Canadian Immunization Research Network (CIRN) Renewal
CIHR · 2024 · Co-investigator
- $4,569,190
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Principal investigator
- $1,142,297
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Principal investigator
2 publications.
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, Martz R, Meyer I, McNeil S, Langley JM, Martins E, Heyward WL, Martin JT
Canadian Immunization Research Network (CIRN) Renewal
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Buchan, Sarah; Cowan, Juthaporn; Dubé, Eve; Greyson, Devon; Hatchette, Todd F; Heffernan, Jane M; Kwong, Jeffrey C; Langley, Joanne M; MacDonald, Shannon E; McNeil, Shelly A; Muller, Matthew P; Parsons Leigh, Jeanna J; Sadarangani, Manish; Top, Karina A
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Modeling And Economic Analysis; Vaccine Safety; Vulnerable Populations
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Canadian Immunization Research Network: COVID-19 Vaccine Readiness
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Hatchette, Todd F; Kellner, James D; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; MacDonald, Shannon E; McNeil, Shelly A; Top, Karina A; Ward, Brian J
Keywords: Adverse Events Following Immunization; Clinical Trials Capacity And Readiness; Immunogenicity; Knowledge Translation; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Hesitancy; Vaccine Modeling; Vaccine Safety And Effectiveness
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Burchell, Ann N; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Doroshenko, Alexander; Dubé, Eve; Gagneur, Arnaud A; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; McNeil, Shelly A; Sadarangani, Manish; Top, Karina A; Ulanova, Marina; Ward, Brian J
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Modeling And Economic Analysis; Vaccine Safety; Vulnerable Populations
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Fisman, David N; Hatchette, Todd F; Isenor, Jennifer; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; MacDougall, Heather A; Mahmud, Salaheddin; McNeil, Shelly A; Naus, Monika; Ogilvie, Gina S; Quach-Thanh, Caroline; Scheifele, David W; Top, Karina A; Van Buynder, Paul; Vaudry, Wendy L; Ward, Brian J; Watts, Tania H; Wilson, Kumanan; Wilson, Sarah
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Safety; Vulnerable Populations
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Hatchette, Todd F; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; Mahmud, Salaheddin; McNeil, Shelly A; Naus, Monika; Quach-Thanh, Caroline; Scheifele, David W; Skowronski, Danuta Maria; Top, Karina A; Vaudry, Wendy L; Ward, Brian J; Watts, Tania H; Wilson, Kumanan; Wilson, Sarah
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Safety; Vulnerable Populations
PHAC/CIHR Influenza Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; De Serres, Gaston; Kwong, Jeffrey C; Loeb, Mark B; McNeil, Shelly A; Scheifele, David W; Ward, Brian J
Keywords: And Effectiveness; Immunogenicity; Influenza; Influenza Serology; Influenza Vaccine; Pandemic; Vaccine Coverage; Vaccine Program Delivery And Evaluation; Vaccine Safety; Vaccine-Associated Adverse Events
PHAC/CIHR Influenza Research Network
Principal investigators: Halperin, Scott A; Bortolussi, Robert A; Collet, Jean-Paul; De Serres, Gaston; Johnson, Marcia M; Kwong, Jeffrey C; McNeil, Shelly A; Scheifele, David W; Ward, Brian J
Keywords: And Effectiveness; Immunogenicity; Influenza; Influenza Vaccine; Pandemic; Vaccine Coverage; Vaccine Program Implementation; Vaccine Safety
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.